Frontage Holdings Corporation Stock price

Equities

1521

KYG3679P1019

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
1.44 HKD +2.13% Intraday chart for Frontage Holdings Corporation -7.10% -37.93%
Sales 2023 260M 2.03B Sales 2024 * 330M 2.58B Capitalization 372M 2.91B
Net income 2023 10M 78.25M Net income 2024 * 24M 188M EV / Sales 2023 2.32 x
Net cash position 2023 * 64.46M 504M Net cash position 2024 * 62.01M 485M EV / Sales 2024 * 0.94 x
P/E ratio 2023
57.1 x
P/E ratio 2024 *
18.6 x
Employees 1,613
Yield 2023 *
-
Yield 2024 *
-
Free-Float 31.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.13%
1 week-7.10%
Current month-13.77%
1 month-13.77%
3 months-31.43%
6 months-29.06%
Current year-37.93%
More quotes
1 week
1.41
Extreme 1.41
1.51
1 month
1.41
Extreme 1.41
1.77
Current year
1.41
Extreme 1.41
2.27
1 year
1.41
Extreme 1.41
2.68
3 years
1.41
Extreme 1.41
9.18
5 years
1.41
Extreme 1.41
9.18
10 years
1.41
Extreme 1.41
9.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 17-05-31
Founder 66 00-12-31
Director of Finance/CFO 48 Jan. 01
Members of the board TitleAgeSince
Director/Board Member 55 18-03-31
Director/Board Member 65 18-03-31
Founder 66 00-12-31
More insiders
Date Price Change Volume
24-03-28 1.44 +2.13% 534,000
24-03-27 1.41 -4.08% 1,676,000
24-03-26 1.47 -0.68% 1,084,000
24-03-25 1.48 -1.99% 1,210,000
24-03-22 1.51 -2.58% 1,144,000

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the People's Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
5
Last Close Price
0.184 USD
Average target price
0.2466 USD
Spread / Average Target
+34.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Frontage Holdings Corporation - Hong Kong S.E.